Introduction

Novo Nordisk stands at a crossroads as analysts dissect the implications of an impending semaglutide patent expiration. With the stock trading at a 10x earnings multiple, market participants are divided over whether the current pricing reflects a genuine opportunity or a trap shaped by looming generic competition.

What Happened

In September 2026, Morgan Stanley downgraded Novo Nordisk A/S (NYSE: NVO) to underweight, citing a projected semaglutide patent cliff that will strip exclusivity across key markets through 2032. The firm's model indicates the blockbuster molecule, which powered roughly 75% of 2026 revenue, will still account for 59% of total sales in 2031, yet the current valuation does not fully account for the resulting revenue shift. The stock slipped 2% following the note and sits 33% below its 52-week high, changing hands at 10.6x earnings.

Why This Matters

The semaglutide patent expiration creates a structural inflection point for Novo's revenue trajectory and valuation framework. While the company's oral obesity pipeline and next-generation candidates like CagriSema and amycretin are positioned as potential successors, their ability to replace lost blockbuster momentum remains unproven. Institutional activity suggests modest accumulation, with 59 hedge funds holding the name in Q2 2026, yet short interest remains negligible, reflecting a divided sentiment between contrarian buyers and cautious bears.

Key Takeaways

  • The 10.6x multiple already embeds aggressive pessimism, making the stock sensitive to any deviation from the projected patent timeline.
  • Patent exclusivity for semaglutide ends in Europe in 2031 and the U.S. in 2032, with generic entry expected to pressure pricing and margins.
  • Novo's next-generation pipeline, including CagriSema and amycretin, offers a defensive narrative, though clinical readouts have been mixed and terminal-value models largely discount these assets.
  • The STEP Young trial, reported in early September 2026, demonstrated efficacy in children aged six to twelve, potentially expanding the franchise base for future successors.
  • Institutional data from Insider Monkey shows 59 hedge funds held NVO in Q2 2026, up from 55 in Q1, while short interest sits near 0.7%, indicating limited bearish pressure despite the bearish note.

Conclusion

Novo Nordisk's current valuation reflects a market that has largely priced in the semaglutide patent cliff, leaving little margin of safety unless the pipeline delivers unexpected breakthroughs. Investors tracking the stock should monitor clinical updates for CagriSema, amycretin, and broader franchise expansion, particularly as the company seeks to replace blockbuster revenue with next-generation therapies. While the contrarian case hinges on accumulated institutional interest and a multiple that may already reflect the worst case, the path forward depends heavily on real-world trial results and the timing of generic entry.